Home > Boards > US Listed > Biotechs >

Alimera Sciences (ALIM)

ALIM RSS Feed
Add ALIM Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 8/5/2020 12:15:25 PM - Followers: 34 - Board type: Free - Posts Today: 0

  https://alimerasciences.com/products/iluvien-for-diabetic-macular-edema-dme/ https://alimerasciences.com/products/patents/


     

Diabetic Retinopathy
  https://alimerasciences.com/areas-of-focus/diabetic-macular-edema-dme/ https://alimerasciences.com/areas-of-focus/retinal-vein-occlusion-rvo/ https://alimerasciences.com/areas-of-focus/age-related-macular-degeneration-amd/

 

Comprehensive Compliance Program Description

I. Introduction

 

Alimera Sciences, Inc. (Alimera) is committed to conducting its business in compliance with all applicable laws, rules, and regulations and the highest standards of ethical conduct.  To this end, we have established and will maintain a Comprehensive Compliance Program (“Compliance Program”) in accordance with the OIG Compliance Program Guidance for Pharmaceutical Manufacturers (the “OIG Guidance”) published by the Office of Inspector General, U.S. Department of Health and Human Services.  Our Compliance Program is a key component of our commitment to adhering to the highest standards of corporate responsibility and fostering a culture of compliance that places a premium on doing business with integrity.  Our Program also incorporates the Code on Interactions with Healthcare Professionals published by the Pharmaceutical Research and Manufacturers of America.

We have designed our Compliance Program to (1) prevent, detect, and remediate violations of applicable laws, rules, and regulations, as well as Alimera’s policies and procedures and (2) promote a culture of the highest ethics within the company.  It is Alimera’s expectation that employees will comply with our Code of Business Conduct and the policies and procedures established in support of that Code.  As the OIG Guidance recognizes, however, the implementation of a Compliance Program cannot guarantee the elimination of improper employee conduct.

As recognized in the OIG Guidance, we have tailored our Compliance Program — the fundamental elements of which we have described below – to fit the unique environment of our company.  Moreover, our Compliance Program is dynamic and we regularly review and enhance our Program to meet our evolving compliance needs.

You may obtain a copy of this Compliance Program description by calling 1-844-445-8843.

II. Overview of Compliance Program

 

Compliance Governance

Compliance Officer. Alimera has appointed a Compliance Officer who is charged with developing, implementing, and monitoring the Compliance Program.  We will ensure that the Compliance Officer has the ability to exercise independent judgment and, as necessary, effectuate change within the company.  The Compliance Officer reports to the President and Chief Executive Officer of Alimera, is a member of Alimera’s Executive Management team, and has direct access to the Alimera Board of Directors.

Compliance Committee. Alimera has established a Compliance Committee made up of Alimera senior management. The role of the Compliance Committee is to advise and assist the Compliance Officer in the development, implementation, and ongoing oversight of the Compliance Program.  The Compliance Committee meets on a regular basis to identify and manage areas of risk and areas of critical focus for the Compliance Program.

Written Standards

Alimera has established written policies and procedures, including our Code of Business Conduct, which articulates our fundamental principles and values and provides a framework for ethical conduct within our company. The Code of Business Conduct establishes our expectation that management, employees, and agents of Alimera act in accordance with all applicable laws, rules, and regulations; Alimera’s policies and procedures; and the highest standards of ethics.

In accordance with California law, Alimera has established an annual spending limit for certain promotional activities directed toward healthcare professionals who prescribe or may influence prescribing in California.  At the present time our annual, per-prescriber spending limit is $1,500. Examples of items that fall within this spending limit are occasional modest meals in connection with informational presentations and educational items.

This annual spending limit does not include payments to healthcare professionals for bona fide consulting or other services.

It is Alimera’s policy to not provide any item of value to any healthcare professional with the intent of influencing that healthcare professional’s prescribing habits.

Education and Training

A crucial element of our Compliance Program is the education and training of our employees on their legal and ethical obligations under applicable laws, rules, regulations, and company policies and procedures.  Alimera regularly communicates our policies and procedures to promote a thorough understanding of the company’s expectations and regularly reviews and updates our training initiatives.

Internal Lines of Communication

Alimera actively fosters dialogue between management and employees.  Our goal is that all employees should know to whom to turn when seeking answers to questions or reporting possible violations of company policies or procedures, and understand that they can make such reports without fear of retaliation.  To that end, we have adopted open-door and non-retaliation policies.  We have a toll-free compliance helpline to which employees of Alimera may anonymously raise questions or report any concerns or suspected violations of applicable laws, rules, regulations, or Alimera policies or procedures.

Auditing and Monitoring

Alimera’s Compliance Program includes monitoring and auditing to evaluate adherence to Alimera’s policies and procedures.  
We note that, in accordance with the OIG Guidance, the nature, extent, and frequency of our compliance monitoring and auditing
may vary according to new regulatory requirements, changes in business practices, and other considerations.

Responding to Potential Violations

When Alimera becomes aware of potential violations of applicable laws, rules, or regulations or company policies or procedures,
the company will promptly investigate such matters and make a determination as to whether the facts substantiate the existence of a violation.  
Alimera will document the conduct of such investigations.

Disciplinary and Corrective Action

While each substantiated violation will be considered on a case-by-case basis, where appropriate we will utilize disciplinary action consistent
with company policy to address violative conduct and to deter future violations.  
We will also work to determine the root cause of the violation and assess whether the violation is due to gaps in company policies or procedures
and take appropriate corrective action designed to prevent future violations.

 

III. California Compliance Declaration

 

Alimera Sciences, Inc. hereby declares that, to the best of our knowledge, information, and belief,
and based upon our good-faith understanding of the statutory requirements, we have, as of March 3, 2015,
established a Comprehensive Compliance Program that is in material compliance with the requirements of California Health and Safety Code §§ 119400-119402.  
While Alimera’s Comprehensive Compliance Program cannot completely eliminate the possibility that an individual employee will engage in improper conduct,
our Program is reasonably designed to prevent and detect violations of applicable laws, rules, and regulations, as well as our own internal policies and procedures.


*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.




 

ALIM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ALIM News: Quarterly Report (10-q) 08/04/2020 04:31:25 PM
ALIM News: Current Report Filing (8-k) 07/30/2020 06:04:47 AM
ALIM News: Alimera Sciences Announces Second Quarter 2020 Financial Results and Provides Corporate Update 07/29/2020 04:05:10 PM
ALIM News: Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update 07/22/2020 08:00:10 AM
ALIM News: Current Report Filing (8-k) 07/10/2020 04:39:32 PM
PostSubject
#1007   News: $ALIM LD Micro Announces Preliminary List of whytestocks 08/05/20 12:15:25 PM
#1006   ALIM surprises on Earnings. Gapping higher in the morning. conix 07/29/20 10:09:28 PM
#1005   ALIM Chart conix 07/27/20 08:16:50 PM
#1004   Alimera Sciences Overview conix 07/24/20 06:39:44 PM
#1003   News: $ALIM Alimera Sciences Initiates Landmark NEW DAY whytestocks 07/09/20 07:15:13 PM
#1002   Alimera Sciences to Participate in the LD Micro mick 12/09/19 07:39:49 PM
#1001   COULD BE HUGE, BUYOUT COMING ????? Alimera Sciences mick 12/09/19 07:35:45 PM
#1000   GOOD EVENING FRIEND/ WOW WOWZER HITTER FER US'INS. mick 12/09/19 07:34:23 PM
#999   wow wowzer read peter/\Alimera Sciences (ALIM) Announces Regulatory mick 12/04/19 06:50:11 PM
#998   News: $ALIM Alimera Sciences to Participate in the whytestocks 12/04/19 03:45:26 PM
#997   $ALIM https://www.streetinsider.com/Corporate+News/Alimera+Sciences+%28ALIM%29+A $Pistol Pete$ 12/04/19 01:35:44 PM
#996   People Wanting This Treatment "THE RIGHT TO TRY"/\Alimera mick 12/04/19 10:28:43 AM
#995   wow/\ $ALIIM/ ih.advfn.com/p.php?pid=staticchart&s=ALIM&p=0&t=17&width=33 mick 12/03/19 10:09:02 AM
#994   even higher/\ALIM 7.09 +0.26 +3.81% USD 9:55AM EST 47,624 mick 12/03/19 10:07:22 AM
#993   maybe buyout peter. huge rewards from $0.20 pps/\ mick 12/03/19 10:06:58 AM
#992   WOW, ALIM mick 12/02/19 01:43:59 PM
#991   https://otcbb.swingtradebot.com/equities/ALIM, WOW mick 12/01/19 11:15:28 AM
#990   ALIM 5.58 +0.60 +12.05% USD 10:45AM EST 57.420k and higher now. mick 11/27/19 12:17:14 PM
#989   'ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera mick 11/15/19 09:27:36 AM
#988   good morning, 11-15-2019 /\'Alimera Sciences (ALIM)' mick 11/15/19 09:25:17 AM
#987   indeed peter, wow last couple of days. 'Alimera mick 11/14/19 08:19:27 PM
#986   Nice close $Pistol Pete$ 11/14/19 08:08:02 PM
#985   News: $ALIM Alimera Sciences Announces Effectiveness of Previously whytestocks 11/14/19 05:00:39 PM
#984   kind ah nice to make 50% on couple mick 11/14/19 04:13:47 PM
#983   $ALIM GAPPER tomorrow!!!! Added more before bell, but mick 11/14/19 04:03:37 PM
#982   nice profit/\ 'Alimera Sciences (ALIM)' ????? mick 11/14/19 03:57:54 PM
#981   ih.advfn.com/p.php?pid=staticchart&s=ALIM&p=0&t=17&width=336&height=112&v mick 11/14/19 03:46:16 PM
#980   $$$$$ALIM, I AM SEEING OVER 0.30 ????? mick 11/14/19 03:43:26 PM
#979   $ALIM/\Recent Trades - Last 10 of 13 mick 11/14/19 09:28:33 AM
#978   * * $ALIM Video Chart 11-13-19 * * ClayTrader 11/13/19 05:48:42 PM
#977   News: $ALIM Alimera Sciences Terminates Equity Purchase Agreement whytestocks 11/13/19 10:19:24 AM
#976   $ALIM/ Recent Trades - Last 10 of 479 mick 11/13/19 10:10:23 AM
#975   this is huge item, cancelled deal for cash/ mick 11/13/19 10:07:52 AM
#974   I DRESSED IBOX UP SOME FOR ALL. Alimera mick 11/13/19 09:48:13 AM
#973   WOW, LESS THAN 24 HR CALL FOR OVER mick 11/13/19 09:46:20 AM
#972   $ALIM/ what ah pre-market opening. wow. ON TARGET mick 11/13/19 09:43:57 AM
#971   Agreed $Pistol Pete$ 11/12/19 03:42:21 PM
#970   Nice call. I am in at $.20 $Pistol Pete$ 11/12/19 03:42:11 PM
#969   I HAD IMPLANTS DONE, $5,000 EACH EYE. mick 11/12/19 01:59:18 PM
#968   #2 $ALIM/\ILUVIEN® Patent Notices mick 11/12/19 01:57:20 PM
#967   $ALIM/\Recent Trades - Last 10 of 1534 mick 11/12/19 01:55:24 PM
#966   https://alimerasciences.com/about-us/comprehensive-compliance-program-descriptio mick 11/12/19 01:39:27 PM
#965   https://alimerasciences.com/areas-of-focus/ mick 11/12/19 01:39:20 PM
#964   https://alimerasciences.com/ For press inquiries: mick 11/12/19 01:34:28 PM
#963   huge read/\Alimera Sciences Announces Third Quarter 2019 Financial mick 11/12/19 01:29:43 PM
#962   $ALIM/\PPS $0.25 OR BETTER BEFORE REVERSE SPLIT ????? mick 11/12/19 01:21:41 PM
#961   $ALIM/\Alimera Sciences EPS in-line, beats on revenue,Oct. 29, mick 11/12/19 01:20:26 PM
#960   $ALIM/\WITH BETTER REVENUES REPORTED , I SEE AH mick 11/12/19 01:18:49 PM
#959   NEWS/\Alimera Sciences Announces Equity Purchase Agreement for up mick 11/12/19 01:15:14 PM
#958   PEOPLE WITH RETINA PROBLEMS , PEOPLE DID GO mick 11/12/19 01:14:22 PM
PostSubject